OxFORD Asset Management LLP grew its holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 267.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,308 shares of the company’s stock after purchasing an additional 44,610 shares during the period. OxFORD Asset Management LLP owned about 0.15% of Pacira Pharmaceuticals worth $2,924,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock worth $145,180,000 after purchasing an additional 3,172,817 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in Pacira Pharmaceuticals during the first quarter worth $22,867,000. Eaton Vance Management bought a new position in Pacira Pharmaceuticals in the second quarter valued at $19,519,000. Russell Investments Group Ltd. grew its position in Pacira Pharmaceuticals by 3,599.8% in the second quarter. Russell Investments Group Ltd. now owns 283,513 shares of the company’s stock valued at $13,524,000 after purchasing an additional 275,850 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in Pacira Pharmaceuticals by 788.0% in the first quarter. Ameriprise Financial Inc. now owns 282,531 shares of the company’s stock valued at $12,884,000 after purchasing an additional 250,714 shares in the last quarter.

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) opened at 37.80 on Tuesday. The firm’s 50-day moving average price is $37.01 and its 200 day moving average price is $43.59. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95. The firm’s market cap is $1.52 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The business had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.21 earnings per share. Analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.17) EPS for the current year.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the completion of the transaction, the chief accounting officer now owns 21,312 shares in the company, valued at approximately $783,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 over the last quarter. 6.60% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/oxford-asset-management-llp-acquires-44610-shares-of-pacira-pharmaceuticals-inc-pcrx/1605255.html.

Several equities research analysts have issued reports on the stock. CIBC assumed coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a “market perform” rating on the stock. Wedbush reissued an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 21st. UBS AG began coverage on shares of Pacira Pharmaceuticals in a research note on Wednesday, September 6th. They set a “market perform” rating for the company. Royal Bank Of Canada restated an “outperform” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 5th. Finally, Mizuho restated a “buy” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $53.00.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.